91P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)

L Antonuzzo,H Takahashi,J.O Park,A Sookprasert,R Gillmore,S-S Yang,J.E Cundom,M Petrova,G.M Vaccaro,M Holmblad,J Xiong,K Heider,N Rokutanda,D-Y Oh

doi:10.1016/j.annonc.2022.10.127

91P Immune-mediated adverse event (imAE) incidence, timing and association with efficacy in the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in advanced biliary tract cancer (BTC)

L Antonuzzo, H Takahashi + Show 12 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.127

Copy DOI

Journal: Annals of Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Seoul National University, University of Florence, Khon Kaen University, Osaka International Cancer Institute, The Royal Free Hospital, Taichung Veterans General Hospital

#Advanced Biliary Tract Cancer #Immune Checkpoint Inhibitor + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

In TOPAZ-1 (NCT03875235), D + GC significantly improved overall survival (OS) vs PBO + GC for patients (pts) with advanced BTC (Oh et al. NEJM Evid 2022; https://doi.org/10.1056/EVIDoa2200015). D (immune checkpoint inhibitor) may cause imAEs; imAEs have been associated with improved OS (Zhou et al. BMC Med 2020;18:87).

Full Text